Biopharmaceutical

A new cross-border pharmaceutical partnership has emerged as BahiaFarma, Biocon, and Bionovis signed a memorandum of understanding aimed at expanding cooperation in biopharmaceutical development and manufacturing. The agreement underscores a shared commitment to improving access to complex and affordable medicines, particularly in emerging markets.

India’s Union Budget has delivered a decisive push to the health care and biopharmaceutical sectors, underscoring innovation, self-reliance, and long-term resilience. Through targeted allocations, policy incentives, and institutional support, the government has signaled its intent to strengthen research capabilities, accelerate domestic manufacturing, and improve access to advanced medical solutions. The measures are designed to move the sector beyond cost-led growth toward innovation-driven value creation.

The Union government is considering a Rs. 10,000 crore investment proposal for the biopharmaceutical sector in the forthcoming budget, signaling a strategic shift toward innovation-led healthcare growth. The planned allocation aims to strengthen research and development, expand advanced manufacturing capabilities, and reduce reliance on imported biologics and critical inputs. The move reflects lessons drawn from recent global health disruptions and aligns with India’s ambition to emerge as a global biopharma and life sciences hub.

Global biopharmaceutical major GlaxoSmithKline (GSK) has launched a new portfolio of oncology therapies in India, specifically designed to address gynaecological cancers such as ovarian and endometrial malignancies. The move underscores GSK’s strategy to strengthen its presence in the oncology segment while expanding treatment options for patients who have limited access to advanced therapies.

In a significant step toward strengthening India’s position in the global pharmaceutical value chain, Telangana Chief Minister Revanth Reddy inaugurated the Global Capability Center (GCC) of Eli Lilly and Company in Hyderabad. The facility is poised to become a critical hub for the American biopharmaceutical giant’s innovation, technology, and operational excellence. The launch reaffirms Hyderabad’s emergence as a magnet for multinational healthcare investment and digital transformation in life sciences.

Biocon Biologics, a leading player in the global biopharmaceutical space, has appointed Deepali Naair as the Head of Brand and Corporate Communications. With this strategic hire, the company aims to elevate its global brand visibility and strengthen its narrative in a competitive and rapidly evolving sector. Naair brings a wealth of experience in marketing, digital strategy, and corporate reputation management, having previously led brand mandates across financial services, technology, and consumer sectors.